Pimavanserin

SOURCE CAVEAT — NO UK SPC: the source bundle contains no eMC record for pimavanserin, so this dose is taken from the US FDA prescribing information for NUPLAZID (Acadia Pharmaceuticals, label date 2026-06-18, https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2199d74b-37ed-408c-97af-ef036899216b), §2.1. US labelling may differ from UK practice and pimavanserin may not hold a UK marketing authorisation — the clinician must verify licensing status and dose against current UK prescribing references before this is published. INDICATION on the US label: hallucinations and delusions associated with Parkinson's disease psychosis (the label carries a boxed warning on increased mortality in elderly patients with dementia-related psychosis, and states NUPLAZID is not approved for treating patients with dementia who experience psychosis unless their hallucinations and delusions are related to Parkinson's disease). ADMINISTRATION: can be taken with or without food; capsules can be taken whole, or opened and the entire contents sprinkled over a tablespoon (15 mL) of applesauce, yogurt, pudding or a liquid nutritional supplement — consume the drug/food mixture immediately without chewing and do not store for future use. DOSAGE MODIFICATION FOR CYP3A4 INHIBITORS: with strong CYP3A4 inhibitors the recommended dose is 10 mg taken orally as one tablet once daily. CYP3A4 INDUCERS: avoid concomitant use of strong or moderate CYP3A4 inducers. GERIATRIC: no dose adjustment is required for elderly patients. PAEDIATRIC: safety and effectiveness in paediatric patients have not been established — no paediatric dose is stated and none should be inferred; verify any under-18 use against a children's formulary. No renal impairment guidance was present in the sections retrieved — verify. Several label sections were truncated at the source-fetch limit.